Please use this identifier to cite or link to this item:
DC FieldValue
dc.titleObstructive sleep apnea therapy for cardiovascular risk reduction-Time for a rethink?
dc.contributor.authorDissanayake, Hasthi U
dc.contributor.authorColpani, Juliana T
dc.contributor.authorSutherland, Kate
dc.contributor.authorLoke, Weiqiang
dc.contributor.authorMohammadieh, Anna
dc.contributor.authorOu, Yi-Hui
dc.contributor.authorde Chazal, Philip
dc.contributor.authorCistulli, Peter A
dc.contributor.authorLee, Chi-Hang
dc.identifier.citationDissanayake, Hasthi U, Colpani, Juliana T, Sutherland, Kate, Loke, Weiqiang, Mohammadieh, Anna, Ou, Yi-Hui, de Chazal, Philip, Cistulli, Peter A, Lee, Chi-Hang (2021-11-17). Obstructive sleep apnea therapy for cardiovascular risk reduction-Time for a rethink?. Clin Cardiol. ScholarBank@NUS Repository.
dc.description.abstractObstructive sleep apnea (OSA) is a highly prevalent and underdiagnosed medical condition, which is associated with various cardiovascular and metabolic diseases. The current mainstay of therapy is continuous positive airway pressure (CPAP); however, CPAP is known to be poorly accepted and tolerated by patients. In randomized controlled trials evaluating CPAP in cardiovascular outcomes, the average usage was less than 3.5 hours, which is below the 4 hours per night recommended to achieve a clinical benefit. This low adherence may have resulted in poor effectiveness and failure to show cardiovascular risk reduction. The mandibular advancement device (MAD) is an intraoral device designed to advance the mandible during sleep. It functions primarily through alteration of the jaw and/or tongue position, which results in improved upper airway patency and reduced upper airway collapsibility. The MAD is an approved alternative therapy that has been consistently shown to be the preferred option by patients who are affected by OSA. Although the MAD is less efficacious than CPAP in abolishing apnea and hypopnea events in some patients, its greater usage results in comparable improvements in quality-of-life and cardiovascular measures, including blood pressure reduction. This review summarizes the impact of OSA on cardiovascular health, the limitations of CPAP, and the potential of OSA treatment using MADs in cardiovascular risk reduction.
dc.subjectblood pressure
dc.subjectcardiovascular risk
dc.subjectcoronary artery disease
dc.subjectsleep apnea
dc.subjectupper airway
dc.contributor.departmentDEPT OF DENTISTRY
dc.description.sourcetitleClin Cardiol
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Obstructive sleep apnea therapy for cardiovascular risk reduction-Time for a rethink?Published version1.58 MBUnknown


Obstructive sleep apnea therapy for cardiovascular risk reduction-Time for a rethink? .pdfPublished version1.58 MBAdobe PDF

CLOSED (no policy)


Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.